...for the anti-CEACAM5-DM4 ADC SAR408701 supports further...
During the early dose escalation phase, preliminary anti-tumor activity was observed with objective response reported in 3 patients with CRC and 1 patient with GC. In an interim analysis of an ongoing expansion